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AbstrAct
Objectives Accurate sizing of the left atrial appendage 
(LAA) is essential when performing percutaneous LAA 
closure. This study aimed to compare different LAA 
imaging modalities and sizing methods in order to obtain 
successful LAA closure.
Background Percutaneous LAA closure is an increasingly 
used treatment strategy to prevent stroke in patients with 
atrial fibrillation. LAA sizing has typically been done by 
2D-transoesophageal echocardiography (TEE).
Methods Patients who had a preprocedural TEE and 
preprocedural and postprocedural multislice CT (MSCT) 
were identified. Preprocedural measurements of LAA ostia 
and landing zones by 2D-TEE, MSCT and angiography 
were collected and analysed for those patients with 
successful LAA closure - i.e. with no contrast leakage at 
3-month follow-up MSCT.
Results The study population (n=67) had a mean 
CHA
2DS2-VASc score of 3.0 and HAS-BLED score 
of 2.7. Fifty-eight patients (87%) were identified to 
have successful LAA closure. Based on MSCT, 48 LAA 
sizings (83%) resulted in a correct LAA closure device 
size selection, whereas with 2D-TEE sizing, only 33 
measurements (57%) would have resulted in a correct 
device size selection (p<0.01). Using adapted Bland-
Altman method, MSCT-based perimeter-derived mean 
diameter was shown to be the best parameter to guide 
LAA device size selection for â€˜closed-endâ€™ devices 
(Amulet, WatchmanFLX), whereas the maximal diameter 
was the best parameter for the â€˜open-endâ€™ 
Watchman device.
Conclusions Preprocedural MSCT-based LAA closure 
device size selection proves to be a more accurate method 
than conventional 2D-TEE-based sizing. Depending on 
the LAA closure device design, perimeter-derived mean 
diameter or maximal diameter could be the better sizing 
method.
IntroductIon
Percutaneous left atrial appendage (LAA) 
closure is being increasingly used as a treat-
ment strategy to prevent stroke in patients 
with atrial fibrillation (AF). The current 
indications for percutaneous LAA closure 
vary geographically. Recently, the European 
Society of Cardiology confirmed a class 
IIB recommendation for patients with AF 
and contraindication(s) for long-term oral 
anticoagulant treatment.1 In the USA, the 
Watchman device (Boston Scientific, Massa-
chusetts, USA) was approved by the Food 
and Drug Administration in 2015 for stroke 
prevention in patients with AF who have ‘an 
appropriate rationale to seek a non-pharma-
cologic alternative to warfarin, taking into 
account the safety and effectiveness of the 
device compared to warfarin’.
In the 4-year follow-up from PROTECT-AF, 
patients with percutaneous LAA closure were 
found to have lower rates of haemorrhagic 
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Key questIons
What is already known about this subject?
Accurate sizing of the left atrial appendage (LAA) is 
essential when performing percutaneous LAA closure. 
2D-transoesophageal echocardiography (TEE) is 
the officially recommended imaging modality in the 
company’s instructions for use; however, other imaging 
modalities could also be used.
What does this study add?
Preprocedural multislice CT (MSCT)-based LAA closure 
device size selection proves to be a more accurate 
method than conventional 2D-TEE-based sizing, with 
a lower rate of residual LAA leakage. Depending on 
the LAA device design, MSCT-based perimeter-derived 
mean diameter is the best parameter to guide device 
size selection for ‘closed-end’ devices (Amulet/
WatchmanFLX), whereas maximal diameter is the best 
parameter for the ‘open-end’ Watchman device.
How might this impact on clinical practice?
With a more accurate preprocedural LAA sizing, the 
next step will be to investigate whether preprocedural 
MSCT-based sizing in combination with intracardiac 
echocardiography-guided LAA device implantation 
could become the new standard, opening up the 
possibility for LAA closure under local anaesthesia.
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Table 1 Baseline characteristics of study population (n=67)
Patient characteristics
  Age, years  74±7
  Female 36 (54%)
  Hypertension 41 (61%) 
  Diabetes mellitus 16 (24%)
  Stroke/TIA/thromboembolism 37 (55%)
  Vascular disease 11 (16%)
  Congestive heart failure 5 (7%)
  Abnormal liver function 1 (1%)
  Abnormal renal function 9 (13%)
  Labile INRs 2 (3%)
  Indication for antithrombotic medication 17 (25%)
  Alcohol 3 (4%)
  CHA2DS2-VASc score  3.0±1.6
  HAS-BLED score  2.7±0.9
 Procedural characteristics
  Anaesthesia/intraprocedural imaging
   G.A. with TEE guidance 28 (42%)
   L.A. with ICE guidance 39 (57%)
  LAA closure device
   Amulet 44 (66%)
   Watchman 11 (16%)
   WatchmanFLX 12 (18%)
  Procedure time (min)  46 ± 13
  Contrast volume (mL)  135 ± 42
 Postprocedural medication
  Single antiplatelet agent 4 (6%)
  Double antiplatelet therapy 63 (94%)
  Oral anticoagulation –
G.A, general anaesthesia; ICE, intracardiac 
echocardiography; INR, international normalised ratio; L.A, local 
anaesthesia; LAA, left atrial appendage; TEE, transoesophageal 
echocardiography; TIA, transient ischaemic attack.
stroke as well as cardiovascular and all-cause mortality.2 
Although these results are promising, percutaneous LAA 
closure carries some procedural risks such as cardiac 
perforation with pericardial effusion. Undersizing of the 
device may lead to significant peridevice leakage or even 
device embolisation, while oversizing of the device may 
cause tamponade or also device embolisation.3 4 In order 
to improve procedural and clinical outcomes, optimal 
LAA imaging and sizing is essential.
Although transoesophageal echocardiography (TEE) 
has been the main imaging modality for LAA assessment 
in most studies and centres, other imaging modalities 
such as multislice CT (MSCT) and intracardiac echocardi-
ography (ICE) could be considered and are increasingly 
used.
In this retrospective study, we aimed to compare the 
accuracy of different LAA imaging and sizing modalities 
in order to obtain successful percutaneous LAA closure.
Methods
study population
In the period September 2014 to August 2016, 129 patients 
underwent percutaneous LAA closure at Rigshospitalet, 
Copenhagen University Hospital, Denmark. For this 
retrospective LAA imaging study, 67 patients who had a 
preprocedural TEE and MSCT as well as a postprocedural 
MSCT at 3 months after LAA closure were identified. All 
patients were fully informed about the procedure and 
provided informed written consent for the procedure 
and data collection. As a routine, preprocedural TEE 
and MSCT were done as outpatient procedures and 500 
mL of saline infusion were given to patients before TEE, 
MSCT and LAA closure to ensure adequate hydration 
and standardised conditions for LAA sizing.
transoesophageal echocardiography
Two-dimensional (2D) TEE was performed using a 
commercially available TEE transducer (Vivid, Philips, 
the Netherlands). The maximal LAA ostium and landing 
zone widths were measured in the mid-oesophageal view 
at 0°, 45°, 90° and 135° angles, according to company 
recommendations. For the Watchman devices (Boston 
Scientific), the maximal LAA ostium width was measured 
from the coronary artery marker to a point 2 cm from the 
tip of the ‘limbus’ at the 0° angle and from the top of the 
mitral valve annulus to a point 2 cm from the tip of the 
‘limbus’ at the other angles. For the Amulet LAA occluder 
(St Jude Medical, Minnesota, USA), the maximal landing 
zone width was measured 10 mm distally from the LAA 
ostium at the level of the left circumflex artery.4
Multislice ct
MSCT imaging was performed using a 320-multidetector 
scanner (Aquilion One Vision Edition, Toshiba Medical 
Systems, Japan). Contrast phase was reconstructed in 
0.5 mm slice thickness with 0.25 mm increment; non-con-
trast phase was reconstructed in 3.0 mm slice thickness 
with 3.0 mm increment (see online supplementary file 
S1).
All MSCT images were analysed using the commercially 
available Osirix software package. Preprocedural LAA 
assessment and sizing was performed by 3D multiplanar 
reconstruction (MPR) using the end-diastolic phase 
series. 3D MPR allows assessment of the LAA anatomy 
in three different planes (sagittal, coronal and axial) 
locked at 90° angles. LAA morphology was classified into 
windsock, chicken wing, cactus and cauliflower. The LAA 
ostium and landing zone for the different devices were 
identified and the minimal diameter, maximal diameter 
and perimeter of these axial LAA views were measured.
All patients included in this study also received a 
control MSCT scan at 3 months postprocedure for assess-
ment of LAA closure device position, device compression, 
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Figure 1 Flow chart. Flow chart showing the number of 
patients with successful percutaneous LAA closure based on 
the evaluation of the 3-month CT follow-up. LAA, left atrial 
appendage; MSCT, multislice CT; TEE, transoesophageal 
echocardiography. 
Figure 2 Postprocedural multislice CT (MSCT) follow-
up. MSCT control scans at 3 months postprocedure to 
assess LAA device position and complete LAA closure. 
(A) Successful LAA closure with an Amulet occluder with 
no contrast leakage into LAA. (B) Unsuccessful LAA 
closure with contrast leakage into LAA due to Amulet 
device undercompression. (C) Unsuccessful LAA closure 
with contrast leakage into LAA due to Amulet device 
overcompression. (D) Successful LAA closure with a 
Watchman LAA closure device with no contrast leakage 
into LAA. (E) Successful LAA closure with a WatchmanFLX 
LAA closure device with no contrast leakage into LAA. (F) 
Unsuccessful LAA closure with contrast leakage into LAA 
due to a rotated, non-occlusive WatchmanFLX closure 
device. LAA, left atrial appendage.
Interventional cardiology
peridevice leakage and device-related thrombosis. In case 
of no contrast leakage into the LAA, the LAA closure was 
considered successful.
Percutaneous LAA closure procedure
Percutaneous LAA closures were performed either under 
general anaesthesia with TEE guidance or with local 
anaesthesia and ICE guidance. Following routine trans-
septal puncture (posterior and slightly inferior), the LAA 
was closed by one of the following three LAA closure 
devices: Amplatzer Amulet LAA occluder, Watchman or 
WatchmanFLX device, as described previously.4 5
statistical analysis
Continuous data are reported as mean±SD, and cate-
gorical variables are reported as number of patients and 
percentages. Categorical data were compared using Fish-
er's exact test, and continuous data using Student's t-test 
or Mann-Whitney's U test, as appropriate. An adapted 
Bland-Altman method was used to investigate the accu-
racy of the different imaging modalities in order to 
obtain successful LAA closure with no contrast leakage 
into the LAA—the 95% limits of agreement (mean differ-
ence ±2 xSD) was calculated for every specific LAA closure 
device and imaging modality. All tests were two sided, and 
p values<0.05 were considered to be statistically signifi-
cant. All analyses were conducted using SPSS statistical 
software V. 23.0 (IBM, Armonk, New York, USA).
resuLts
baseline characteristics
A total of 67 patients were included in this study. The 
mean age of the patient cohort was 74 years and 36 
patients (54%) were female. The average CHA2DS2-
VASc score was 3.0 and HAS-BLED score was 2.7. Three 
different LAA closure devices were used: Amulet (n=44; 
66%), Watchman (n=11; 16%) and WatchmanFLX 
(n=12; 18%). The majority of patients (n=63; 94%) were 
treated with dual antiplatelet therapy during the first 
3 months postimplantation (table 1). A list of indications 
for percutaneous LAA closure can be found in online 
supplementary file S2.
successful LAA closure
Of all 67 patients who underwent percutaneous LAA 
closure and who were planned for a control CT scan 
after 3 months, 1 patient died within 3 months and 8 
other patients were found to have contrast leakage into 
the LAA (figure 1). From the three patients with <10% 
of device compression after implantation, two patients 
(67%) had contrast leakage at control CT scan. In the 
group of patients with 10%–20% of LAA device compres-
sion, only one patient (1/38, 3%) had unsuccessful LAA 
closure with contrast leakage into the LAA. From those 
with >20% device compression, five patients (5/25, 20%) 
had contrast leakage into the LAA (figure 2 and 3).
LAA sizing by different imaging modalities
As those cases with a completely occluded LAA without 
residual LAA leakage can be considered truly successful 
LAA closures, the LAA closure device sizes used in these 
cases can be considered as the ‘optimal’ device size selec-
tion for these specific cases. Hence, further analysis was 
done on patients with successful LAA closure (n=58), 
i.e. with no contrast leakage at 3-month CT follow-up. 
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Figure 3 LAA device compression and LAA leakage. 
Correlation between LAA closure device compression 
rate (%, as assessed on angiography postimplantation) 
and incidence of LAA leakage as observed at 3 months 
multislice CT follow-up. In case of 10%–20% device 
compression, successful LAA closure was obtained in 37 out 
of 38 cases (97%); leakage into the LAA was more frequently 
observed in case of LAA device undercompression or 
overcompression. LAA, left atrial appendage.
Figure 4 LAA sizing by different imaging modalities. The 
calculated mean difference between LAA sizing and final LAA 
closure device size for the different LAA closure devices and 
imaging modalities. This analysis only included successful 
percutaneous LAA closures (n=58). Adapted Bland-Altman 
method was used to calculate the mean difference, 95% 
limits of agreement and Δ limits of agreement. LAA, left atrial 
appendage; TEE, transoesophageal echocardiography.
The differences between the obtained LAA sizings with 
the different imaging modalities and the used LAA 
closure device size—in millimetre—were calculated for 
every single case. Based on these calculations, the mean 
difference and 95% limits of agreement (LoA) could be 
calculated for each combination of LAA closure device 
and sizing method. The LoA width was the narrowest 
for CT-based LAA sizing methods, namely ‘CT-perimeter 
derived (PD) mean diameter’ for the Amulet (Δ 5.6 mm) 
and WatchmanFLX device (Δ 6.0 mm), and ‘CT-max 
diameter’ for the Watchman device (Δ 5.2 mm). These 
widths were narrower than 2D-TEE and angio-derived 
values, indicating that CT-based sizing methods were the 
most accurate (figure 4).
Figure 5 shows Bland-Altman plots for the three 
different LAA closure devices used in this study and the 
results obtained with 2D-TEE and the most optimal MSCT-
based sizing method. Based on the company-derived LAA 
sizing recommendations (see online supplementary file 
S3) and the MSCT-based recommendation to select the 
first-available larger LAA device size (‘one step up’; see 
online supplementary file S4), the number of correct 
LAA device size selections per imaging modality could be 
calculated. Based on TEE sizing, only 33 out of 58 LAA 
sizings (57%) would have led to the correct LAA closure 
device size, whereas in case of MSCT-based sizing, 48 
out of 58 LAA sizings (83%) would have resulted in the 
correct device size selection (p<0.01; figure 5).
Finally, we can report that LAA sizing by ICE was 
attempted in 10 patients; however, due to the impos-
sibility to assess the LAA in multiple planes and the 
incorrect LAA sizings obtained in these 10 patients (data 
not shown), this LAA sizing modality was not further 
explored. As a result, ICE was solely used as a guidance 
tool for safe transseptal puncture and evaluation of 
successful LAA closure ad hoc.
dIscussIon
Percutaneous LAA closure is an increasingly used treat-
ment strategy to prevent stroke in patients with AF. This 
study aimed to compare the accuracy of different LAA 
imaging modalities and sizing methods in order to opti-
mise procedural outcomes.
From experience in the field of transcatheter aortic 
valve replacement (TAVR), it was learnt that aortic 
annulus sizing by 2D echocardiography results in system-
atic underestimation of the true aortic annular diameter. 
In comparison, CT-based sizing allows a more precise 
assessment of the annulus and, hence, a more accurate 
transcatheter heart valve size selection for TAVR.6Com-
pared with the aortic annulus, the LAA is an even more 
complex structure with a wide range of LAA shapes and 
sizes.7 Despite evaluation of the maximal LAA diameter 
at multiple angles by 2D-TEE, the measured maximal 
group.bmj.com on April 5, 2018 - Published by http://openheart.bmj.com/Downloaded from 
5Chow DHF, et al. Open Heart 2017;4:e000627. doi:10.1136/openhrt-2017-000627
Figure 5 Bland-Altman plots. The adapted Bland-Altman plots for 2D-TEE and optimal CT-guided LAA closure device 
sizing. This analysis only included successful percutaneous LAA closures (n=58). The plots show the difference between LAA 
sizing and final LAA closure device size for the different LAA closure devices and imaging modalities. Considering the official 
TEE-recommended sizing versus CT-based recommendation to select the first-available larger LAA device size (‘one step 
up’), the number of correct sizings per device and imaging modality could be calculated. LAA, left atrial appendage; TEE, 
transoesophageal echocardiography.
Interventional cardiology
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Figure 6 Challenges with 2D-TEE-based LAA sizing. (A) 
The disadvantage of 2D-TEE-guided sizing despite the use 
of multiple angles for assessment of maximal LAA diameter. 
(B) 3D MPR assessment from MSCT allows accurate 
measurement of the perimeter-derived mean diameter and 
maximal LAA diameter. LAA, left atrial appendage; MSCT, 
multislice CT; TEE, transoesophageal echocardiography.
diameter may still underestimate the actual maximal 
LAA diameter (figure 6). This was also reported in a 
study by Shah et al8 showing that 2D-TEE underestimates 
the LAA orifice area compared with 3D-TEE imaging. 
LAA orifice area as measured on cardiac MSCT was well 
correlated with LAA orifice area as measured by 3D-TEE 
but not by 2D-TEE. However, both 2D-TEE and 3D-TEE 
require the availability of a skilled echocardiographer9 
and result in a greater interoperator variability for LAA 
sizing as compared with MSCT in our experience. The 
use of CT-3D MPR allows a more precise assessment of 
LAA morphology, the relationship between LAA and its 
surrounding structures, and a more accurate measure-
ment of the LAA ostium and landing zone.
Despite growing interest in the application of 
CT imaging in preprocedural LAA closure planning, 
there is still no general consensus on how to guide LAA 
device size selection based on CT imaging. By using 
preprocedural and postprocedural CT scans, we were 
able to derive a general guidance for LAA device size 
selection (see online supplementary file S4) based on 
the criterion of ‘successful LAA closure’ without contrast 
leakage into the LAA at 3 months postprocedure. This is 
important since immediate ‘procedural success’ does not 
always lead to actual ‘successful LAA closure’, as observed 
at follow-up CT scan. The definition of successful 
‘LAA closure’ in the PROTECT-AF trial was any seal 
with ≤3 mm width (±2 mm) of peridevice flow. Of the 389 
patients who had 12-month TEE follow-up, 125 patients 
(32%) had persistent flow around the device and 46 
(11.8%) of them had major leakage >3 mm.10 Although 
there is currently no clinical evidence on the association 
between peridevice leakage and the risk of thromboem-
bolism, a stricter definition of ‘successful LAA closure’ 
will be imperative to further improve clinical outcomes 
and broaden the acceptance of this procedure by a larger 
group of referring physicians.
Results in this study indicate that 10%–20% device 
compression immediately after implantation should be 
targeted in order to obtain good rates of ‘successful LAA 
closure’ at long-term follow-up. This is in alignment with 
the company-based recommendations for the Watchman 
devices (see online supplementary file S3); however, a 
company-recommended Amulet lobe compression rate is 
currently not available.
The data in this study also indicate that CT-based LAA 
sizing may be a more accurate method than 2D-TEE-
based and/or angiographic LAA sizing. Although there 
may be concerns that using MSCT as a preprocedural 
planning tool may potentially lead to extra radiation and 
contrast exposure as compared with TEE, the improved 
LAA sizing accuracy obtained with MSCT may shorten 
the actual LAA closure procedure time, radiation expo-
sure, decrease the number of LAA closure devices and 
volume of contrast used during the procedure.11 Based 
on CT sizing, 80%–90% of LAA sizings resulted in the 
correct LAA closure device size selection, whereas in case 
of 2D-TEE-based sizing, only 50%–60% of LAA sizings 
would have led to correct LAA device size selection 
(p<0.01; figure 5).
Until now, conventional TEE-guided device size selec-
tion has been a uniform ‘oversizing approach’ based on 
the maximum LAA ostium width in case of Watchman 
devices and maximum LAA landing zone width in case 
of the Amulet device. However, these different closure 
devices have different designs and structures. The 
behaviour and deployment of these devices may vary, espe-
cially in elliptical LAA anatomies. For LAA closure devices 
with a ‘closed’ nitinol mesh design at its distal end, device 
compression in one plane results in device expansion in a 
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Figure 7 Device-specific CT-based LAA occluder size selection. Preprocedural cross-sectional CT assessment of the LAA 
landing zone. Since the cross section of the LAA landing zone is more often an ellipse, the major axis (maximal diameter) 
and minor axis (minimal diameter) may differ. As the device comes first into contact with the short axis of the LAA during 
deployment, there will be a compressive force onto the device. Depending on the design of the closure device, the device will 
expand or not in a perpendicular plane to the short axis in case of a ‘closed distal end’ or ‘open distal end’ LAA closure device, 
respectively. LAA, left atrial appendage.
Interventional cardiology
perpendicular plane. On the other hand, for LAA closure 
devices with an ‘open’ nitinol mesh design at its distal 
end, device compression in one plane does not have 
any effect on the device size in a perpendicular plane 
(figure 7). For this reason, CT-based LAA closure device 
size selection should differ for the Amulet and Watch-
manFLX—which are ‘closed-end’ devices—from that of 
the Watchman, which is an ‘open-end’ closure device. 
The calculated LoA indicate that for ‘closed-end’ LAA 
closure devices, the best parameter for LAA device size 
selection is PD mean diameter, whereas for ‘open-end’ 
devices, the best parameter seems to be the maximal LAA 
diameter. The latter finding also indicates that sizing 
for the ‘open-end’ Watchman device is most likely more 
forgiving. When implanting ‘closed-end’ devices, too 
liberal oversizing may result in severe device underex-
pansion and, hence, a lot of ‘stored energy’ in the device, 
thereby increasing the risk of device embolisation. This 
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difference in device characteristics and LAA sizing may 
have been unknown or ignored with the launch of the 
WatchmanFLX device, resulting in an excess number of 
device embolisations.
Finally, we would like to comment on the advantages 
and limitations connected with the use of ICE guidance 
during the procedure. First, by using ICE only during 
the procedure, this approach has created more flexibility 
in our scheduling as we plan LAA closure procedures 
without the need for an anaesthesiologist and/or TEE 
expert. Procedures can be performed with local anaes-
thesia only, without the need for sedative medication. 
Clearly, a disadvantage is the cost of the ICE probe which 
substantially adds extra costs. Another issue with ICE is the 
limitation to assess peridevice leakage in multiple planes 
after implantation. However, as supported by recent data 
reported by Bieliauskas et al,11 the incidence of residual 
LAA leakage was extremely low in case of preprocedural 
LAA sizing with MSCT and periprocedural ICE guidance.
LIMItAtIons
An obvious limitation of this retrospective study is the rela-
tively limited number of patients included. Also the fact that 
both imaging tools were available to the operator before 
the actual procedure may have influenced the final LAA 
closure device size selection. Moreover, 3D-TEE data were 
not available. The unique aspect of this study is, however, 
that both preprocedural and postprocedural MSCT was 
available for all included patients, making the definition of 
successful LAA closure more solid.
concLusIons
This study indicates that MSCT-based LAA device size 
selection may be a more accurate method than conven-
tional TEE-based sizing. Depending on the LAA device 
design, maximal or PD mean diameter could be the 
better sizing method. In addition, 10%–20% device 
compression postimplantation should be targeted in 
order to obtain complete LAA closure at long-term 
follow-up.
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